Serum CXCL16 as a Novel Biomarker of Coronary Artery Disease in Type 2 Diabetes Mellitus: a Pilot Study.
OBJECTIVE
To explore the diagnostic value of serum C-X-C chemokine ligand 16 (CXCL16) in subjects with diabetic coronary artery disease (T2DM-CAD).


METHODS
One hundred twenty Chinese subjects, including patients with coronary artery disease (CAD group), diabetic coronary artery disease (T2DM-CAD group), type 2 diabetes mellitus (T2DM group), and healthy controls of similar age and gender (control group), were enrolled in this study. Serum CXCL16 was detected by a sandwich-type enzyme linked immunosorbent assay (ELISA). Simultaneously, other clinical biochemical parameters such as high-sensitivity C-reactive protein (hs-CRP), uric acid (UA), and glucose (Glu) were tested based on standard methods.


RESULTS
Compared to the levels in the CAD group (3.912±1.061 mg/L) and the T2DM group (4.115±0.876 mg/L), the levels of serum CXCL16 in the T2DM-CAD group were significantly increased (5.707±1.404 mg/L, P<0.01). In the T2DM-CAD group, serum CXCL16 concentrations correlated positively with hs-CRP (r=0.772, P<0.001) and uric acid levels (r=0.476, P<0.01). Multiple linear regression analysis indicated that hs-CRP might be the only influencing factor for serum CXCL16 levels (β=0.772, P<0.001). Furthermore, in the T2DM-CAD group/T2DM group, the area under the curve of CXCL16 was 0.824, and the area under the curve of hs-CRP was 0.842; no significant difference was found (z=0.245, P>0.05).


CONCLUSIONS
Serum CXCL16 may be a novel biomarker for the diagnosis of patients with T2DM-CAD.
Cell Biological Therapy Center, Kunming General Hospital of Chengdu Military Command, Kunming, Yunnan, People's Republic of China Clinical College of Kunming General Hospital of Chengdu Military Command, Kunming Medical University, Kunming, People's Republic of China.
Fang
F
Zhou
Cell Biological Therapy Center, Kunming General Hospital of Chengdu Military Command, Kunming, Yunnan, People's Republic of China.
Jinxiang
J
Wang
Department of Clinical Laboratory, Kunming General Hospital of Chengdu Military Command, Kunming, Yunnan, People's Republic of China.
Ke
K
Wang
Cell Biological Therapy Center, Kunming General Hospital of Chengdu Military Command, Kunming, Yunnan, People's Republic of China.
Xiangqing
X
Zhu
Cell Biological Therapy Center, Kunming General Hospital of Chengdu Military Command, Kunming, Yunnan, People's Republic of China.
Rongqing
R
Pang
Department of Clinical Laboratory, Kunming General Hospital of Chengdu Military Command, Kunming, Yunnan, People's Republic of China.
Xuemei
X
Li
Cell Biological Therapy Center, Kunming General Hospital of Chengdu Military Command, Kunming, Yunnan, People's Republic of China zhguxu@aliyun.com xinghuapan@aliyun.com.
Guangxu
G
Zhu
Cell Biological Therapy Center, Kunming General Hospital of Chengdu Military Command, Kunming, Yunnan, People's Republic of China zhguxu@aliyun.com xinghuapan@aliyun.com.
Xinghua
X
Pan
D000368:Aged; D019540:Area Under Curve; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism; D016022:Case-Control Studies; D000075743:Chemokine CXCL16; D019743:Chemokines, CXC / Q000097:blood*; D003324:Coronary Artery Disease / Q000097:blood*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D005260:Female; D006801:Humans; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D012372:ROC Curve; D051116:Receptors, Scavenger / Q000097:blood*
D015415:Biomarkers; C423727:CXCL16 protein, human; D000075743:Chemokine CXCL16; D019743:Chemokines, CXC; D051116:Receptors, Scavenger; D002097:C-Reactive Protein
CAD; CXCL16; T2DM; hs-CRP